Privacy pods were being operated at the American Dream mall in the Meadowlands without the necessary permits and subsequently were shut down pending those permits ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

Pod coffee makers aren’t for everyone, but they are a great option for anyone who needs quick and easy access to caffeine at home. I know this because as a single, working mom with ADHD, I am ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company. But it ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

LISBON, Feb 5 (Reuters) - Novo Banco's planned initial public offering would be beneficial for the Portuguese banking sector, Bank of Portugal Governor Mario Centeno said on Wednesday, but he ...

Lone Star Funds is selecting advisers to explore a possible sale or initial public offering of Portuguese lender Novo Banco SA, according to people familiar with the matter. The private equity ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.